



ABRATECH Corporation

Contact: Don L. Jewett
Location: Sausalito, CA
Email: dli@abratech.com
Tel: 415.331.8775
Website: <http://www.abratech.com>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: **Medical Devices**

Company Overview: We develop state-of-the-art evoked-response methodology directed towards new clinical uses. Our Research Director has an excellent track record for these goals, a record established first in academe, and now sustained in the invention and development of Q-Sequence Deconvolution (QSD). QSD has detected brain activity never previously observed, nor even suspected. We collaborate with clinicians and equipment manufacturers to demonstrate the clinical uses.

Target Market(s): **Major hospitals and clinics**

Key Value Drivers

Technology*: Q-Sequence Deconvolution (QSD) is a novel, patented algorithm that permits detection of evoked-response waveforms that are overlapped in time because the response is longer than the time between stimuli.

Competitive Advantage: QSD permits stimulus rates to be increased with the consequence that *sensitivity* to pathology is *increased*, while waveform accuracy is maintained. When the stimulus rate is above sensory fusion, new brain activity is evident (A-waves). No other methods show this phenomenon, because of their inherent limitations.

Plan & Strategy: Collaborations with clinicians and equipment manufacturers, to determine and document the unique advantages of QSD.

Management

Leadership:

Virginia H. Meyer, J.D.
President

Don L. Jewett, M.D., D.Phil. (Oxon)
Vice President and Research Director

Product Development:

Memory retention under light anesthesia
Coma Monitoring and Analysis
Newborn Screening
Cortical development during childhood
Attention Deficit Disorder
Traumatic Brain Injury, concussion
Epilepsy treatment
Neuronal Source Localization

